Lake Zurich's Fresenius Kabi debuts drug
Global health care company Fresenius Kabi announced Monday it has introduced Dexmedetomidine Hydrochloride Injection in the United States.
The drug is available immediately in 200mcg per 2mL single dose vials.
The injection was approved by the U.S. Food and Drug Administration in September. It is the equivalent to Precedex and used for sedation of patients before or during surgical and other procedures, the company said.
"Dexmedetomidine is a welcome addition to our anesthesia portfolio, further enhancing the breadth and depth of the medications we provide for sedation in hospital and surgery-center settings," said John Ducker, president and CEO of Fresenius Kabi USA, based in Lake Zurich.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.